Drug
Fevipiprant clinical trials
Also written QAW039.
- studies test it
- 18
- open now
- 0
- in phase 3
- 7
- first study started
- 2010
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 12
Who runs them
Industry 18 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fevipiprant is read from its arms, and is right about nine times in ten.
Testing it · 18
- Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.CompletedPhase 3Novartis PharmaceuticalsNCT02555683Written as QAW039
- Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT03226392Written as QAW039
- Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT03215758Written as QAW039
- Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With AsthmaTerminatedPhase 2Novartis PharmaceuticalsNCT03650400Written as Fevipiprant
- Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT03681093Written as Fevipiprant 150 mg
- Systemic Corticosteroids Avoidance Study in Severe Asthma PatientsTerminatedPhase 3Novartis PharmaceuticalsNCT03629249Written as QAW039 150 mg once daily
- A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With EosinophiliaTerminatedPhase 2Novartis PharmaceuticalsNCT03810183Written as QAW039
- Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.CompletedPhase 3Novartis PharmaceuticalsNCT02563067Written as QAW039
- Dose Finding Study for QAW039 in AsthmaCompletedPhase 2Novartis PharmaceuticalsNCT01437735Written as QAW039
- Efficacy, Safety, and Pharmacokinetics of QAW039CompletedPhase 2Novartis PharmaceuticalsNCT01253603Written as QAW039 capsules once daily for 28 days
- Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT03048448Written as Fevipiprant
- Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT03087942Written as QAW039
- Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentTerminatedPhase 3Novartis PharmaceuticalsNCT03052517Written as QAW039 150 mg
- Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.WithdrawnPhase 2Novartis PharmaceuticalsNCT03989635Written as QAW039
- A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01836471Written as QAW039
- A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure ChamberCompletedPhase 2Novartis PharmaceuticalsNCT01804400Written as QAW039
- Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.CompletedPhase 2Novartis PharmaceuticalsNCT01785602Written as QAW039
- Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent AsthmaCompletedPhase 2Novartis PharmaceuticalsNCT01545726Written as QAW039
Codes
What other systems call fevipiprant · ClinicalTrials.gg INT000398
- MeSH (NLM) C000604875fevipiprantOne source NLM
- UNII (FDA) 2PEX5N7DQ4FEVIPIPRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27077292fevipiprantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166588FevipiprantOne source FDA
- DrugBank DB12011One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604875 | fevipiprant | One source NLM |
| UNII (FDA) | 2PEX5N7DQ4 | FEVIPIPRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27077292 | fevipiprant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166588 | Fevipiprant | One source FDA |
| DrugBank | DB12011 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.